Adaptive Responses to Dasatinib-Treated Lung Squamous Cell Cancer Cells Harboring DDR2 Mutations

DDR2 mutations occur in ~4% of lung squamous cell cancer (SCC) where the tyrosine kinase inhibitor dasatinib has emerged as a new therapeutic option. We found that ERK and AKT phosphorylation was weakly inhibited by dasatinib in DDR2-mutant lung SCC cells, suggesting that dasatinib inhibits survival...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Cancer Res
मुख्य लेखकों: Bai, Yun, Kim, Jae-Young, Watters, January M., Fang, Bin, Kinose, Fumi, Song, Lanxi, Koomen, John M., Teer, Jamie K., Fisher, Kate, Chen, Yian Ann, Rix, Uwe, Haura, Eric B.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2014
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4326029/
https://ncbi.nlm.nih.gov/pubmed/25348954
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-14-0505
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन